Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011

Eurosurveillance

Volumn 19, Issue 11, 2014, Pages

  Ruesen, C ^a   van Gageldonk Lafeber, A B ^a   de Vries, G ^a,b   Erkens, C G ^b   van Rest, J ^a,b   Korthals Altes, H ^a   de Neeling, H ^a   Kamst, M ^a   van Soolingen, D ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; BACTERIAL TRANSMISSION; BCG VACCINATION; CLUSTER ANALYSIS; DNA FINGERPRINTING; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; QUALITY CONTROL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TUBERCULOSIS; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; AGE FACTORS; ANTITUBERCULAR AGENTS; CLUSTER ANALYSIS; DNA FINGERPRINTING; FEMALE; HUMANS; INCIDENCE; ISONIAZID; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; STREPTOMYCIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84896447387     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.11.20738     Document Type: Article

References (27)

1. World Health Organization (WHO). Global tuberculosis report 2013. Geneva: WHO; 2013. Available from: http://www. who. int/tb/publications/global_report/en.
2. Nachega JB, Chaisson RE. Tuberculosis drug resistance: a global threat. Clin Infect Dis. 2003; 36(Suppl 1): S24-30. http://dx. doi. org/10. 1086/344657.
3. European Centre for Disease Prevention and Control (ECDC)/World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: ECDC; 2013. Available from: http://ecdc. europa. eu/en/publications/Publications/Tuberculosis-surveillance-monitoring-2013. pdf.
4. World Health Organization (WHO). The Stop TB Strategy. Building on and enhancing DOTS to meet the TB-related Millennium Development Goals, 2006. Geneva: WHO; 2006. Available from: http://www. who. int/tb/publications/2006/who_htm_tb_2006_368. pdf?ua=1.
5. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2010. Available from: http://whqlibdoc. who. int/publications/2010/9789241599191_eng. pdf.
6. Slump E, Erkens CG, van Hunen R, van Rest JF, Schimmel HJ, van Soolingen D. KNCV Tuberculosis Foundation. 'Tuberculose in Nederland 2011', Surveillancerapport over de tuberculosesituatie in Nederland. [Tuberculosis in the Netherlands, Surveillance report]. The Hague: KNVC Tuberculosis Foundation; 2012. Dutch. Available from: http://www. rivm. nl/dsresource?objectid=rivmp: 210602&type=org&disposition=inline&ns_nc=1.
7. Lambregts-van Weezenbeek CS, Jansen HM, Veen J, Nagelkerke NJ, Sebek MM, Van Soolingen D. Origin and management of primary and acquired drug-resistant tuberculosis in The Netherlands: the truth behind the rates. Int J Tuberc Lung Dis. 1998; 2(4): 296-302.
8. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009; 373(9678): 1861-73. http://dx. doi. org/10. 1016/S0140-6736(09)60331-7.
9. Dutch Foundation of the Working Party on Antibiotic Policy (SWAB). Nethmap 2012. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. Nijmegen/Bilthoven: SWAB/Centre for Infectious disease control (CIb) of the National Institute for Public Health and the Environment of the Netherlands (RIVM); 2012. Available from: http://www. swab. nl/swab/cms3. nsf/uploads/E8426668DC9BC944C1257A24006252DE/$FILE/Nethmap_Maran_2012. pdf.
10. Van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993; 31(2): 406-9.
11. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006; 44(12): 4498-510. http://dx. doi. org/10. 1128/JCM. 01392-06.
12. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol. 2007; 45(8): 2662-8. http://dx. doi. org/10. 1128/JCM. 00244-07.
13. Palomino JC, Traore H, Fissette K, Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 1999; 3(4): 344-8.
14. van Soolingen D, de Haas PE, Hermans PW, Groenen PM, van Embden JD. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol. 1993; 31(8): 1987-95.
15. de Beer JL, van Ingen J, de Vries G, Erkens C, Sebek M, Mulder A et al. Comparative study of IS6110 restriction fragment length polymorphism and variable-number tandem repeat typing of Mycobacterium tuberculosis Isolates in the Netherlands, based on a 5-year nationwide survey. J Clin Microbiol. 2013; 51(4): 1193-8. http://dx. doi. org/10. 1128/JCM. 03061-12.
16. de Vries G, Baars HW, Sebek MM, van Hest NA, Richardus JH. Transmission classification model to determine place and time of infection of tuberculosis cases in an Urban Area. J Clin Microbiol. 2008; 46(12): 3924-30. http://dx. doi. org/10. 1128/JCM. 00793-08.
17. Lambregts-van Weezenbeek CS, Sebek MM, van Gerven PJ, de Vries G, Verver S, Kalisvaart NA, et al. Tuberculosis contact investigation and DNA fingerprint surveillance in The Netherlands: 6 years' experience with nation-wide cluster feedback and cluster monitoring. Int J Tuberc Lung Dis. 2003; 7(12 Suppl 3): S463-70.
18. Central Bureau of Statistics (CBS). StatLine. The Hague: CBS. [Accessed 19 Mar 2014]. Available from: http://statline. cbs. nl/statweb/?LA=en.
19. Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One. 2011; 6(7): e22927. http://dx. doi. org/10. 1371/journal. pone. 0022927.
20. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61(2): 158-63. http://dx. doi. org/10. 1136/thx. 2005. 045963.
21. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011; 44(1): 106-10. http://dx. doi. org/10. 1038/ng. 1038.
22. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis. 2000; 182(6): 1788-90. http://dx. doi. org/10. 1086/317598.
23. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; 13(12): 1456-66.
24. Espinal MA, Laszlo AP, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001; 344(17): 1294-303. http://dx. doi. org/10. 1056/NEJM200104263441706.
25. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375(9728): 1830-43. http://dx. doi. org/10. 1016/S0140-6736(10)60410-2.
26. Mulder C, van Deutekom H, Huisman EM, Meijer-Veldman W, Erkens CG, van Rest J, et al. Coverage and yield of tuberculosis contact investigations in the Netherlands. Int J Tuberc Lung Dis. 2011; 15(12): 1630-7. http://dx. doi. org/10. 5588/ijtld. 11. 0027.
27. de Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis. 2003; 7(2): 145-52.